Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Cronos Group Inc.NASDAQ: CRON
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $40M a year earlier. Over 3 fiscal years it compounded at -29.3% a year.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, down 3.5 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 40M USD
- Year-over-year change
- —
- 4-year CAGR
- -23.6%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 192.24M | +70.0% |
| FY2022 | 2022-12-31 | 113.08M | -3.9% |
| FY2021 | 2021-12-31 | 117.68M | — |
Short-term Investments vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's Mar 2026 short-term investments of $0 is the 8th highest of the 11 companies compared; the peer median is $138.16M.
- Its year-over-year change of -100.0% is the lowest of 8, against a peer median of +50.7%.
- Short-term investments amounts to 0.0% of total assets for CRON, versus a peer median of 8.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $411.79M | +3.1% | -4.6% | 56.8% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $398.73M | +75.1% | — | 80.1% |
| Aug 2026 | $328.01M | -6.4% | +12.2% | 27.4% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $199.62M | +82.3% | — | 47.8% |
| Mar 2026 | $153.11M | +50.7% | — | 9.3% | |
| Mar 2026 | $123.21M | +127.7% | +78.9% | 7.5% | |
| Mar 2026 | $57.87M | -72.4% | -24.4% | 4.8% | |
| Mar 2026 | $0 | -100.0% | -29.3% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CRON) | $138.16M | +50.7% | +3.8% | 8.4% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 886.97M | 764.64M | 669.29M | 858.81M | 791.79M |
| Short-term Investments | 117.68M | 113.08M | 192.24M | 0 | 40M |
| Net Receivables | 33.29M | 31.29M | 35.88M | 29.77M | 57.2M |
| Inventory | 32.8M | 37.56M | 30.5M | 33.15M | 46.75M |
| Other Current Assets | 0 | 7.11M | 5.41M | 14.39M | 8.34M |
| Total Current Assets | 1.08B | 960.16M | 933.31M | 936.11M | 944.09M |
| Property, Plant & Equipment (Net) | 82.95M | 62.83M | 60.82M | 134.58M | 147.29M |
| Goodwill | 1.1M | 1.03M | 1.06M | 63.45M | 66.48M |
| Intangible Assets | 18.08M | 26.7M | 21.08M | 11.13M | 8.89M |
| Long-term Investments | 135.16M | 89.75M | 54.74M | 2.81M | 7.66M |
| Tax Assets | 0 | 0 | 226K | 2.57M | 1.89M |
| Other Non-current Assets | 80.74M | 72.54M | 69.04M | 15.53M | 20.85M |
| Total Non-current Assets | 318.02M | 252.85M | 206.96M | 230.07M | 253.05M |
| Total Assets | 1.4B | 1.21B | 1.14B | 1.17B | 1.2B |
| Account Payables | 11.11M | 11.16M | 12.13M | 16.97M | 11.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 3.59M | 37.09M | 11.76M | 11.84M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 14.38M | 15K | 102K | 40K | 20.11M |
| Total Current Liabilities | 54.37M | 68.12M | 41.4M | 49.7M | 48.19M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 81K | 0 | 181K | 3.56M | 4.09M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.91M | 1.38M | 1M | 1.07M | 733K |
| Total Non-current Liabilities | 9.09M | 3.93M | 2.74M | 5.63M | 5.99M |
| Total Liabilities | 63.46M | 72.05M | 44.14M | 55.33M | 54.18M |
| Common Stock | 595.5M | 611.32M | 662.17M | 669.88M | 661.78M |
| Retained Earnings | 659.42M | 490.68M | 416.72M | 457.71M | 447.76M |
| Accumulated OCI | 49.87M | (797K) | 20.68M | (63.53M) | (16.84M) |
| Other Stockholders Equity | 0 | 0 | (48.45M) | 0 | 0 |
| Minority Interest | (2.97M) | (2.92M) | (3.45M) | 46.92M | 49.06M |
| Total Equity | 1.33B | 1.14B | 1.1B | 1.11B | 1.14B |
| Total Debt | 9.81M | 3.88M | 2.55M | 2.02M | 1.51M |
| Net Debt | (877.17M) | (760.77M) | (666.74M) | (856.79M) | (790.29M) |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.